1887
Volume 2015, Issue 1
  • ISSN: 2305-7823
  • EISSN:
Preview this article:
Zoom in
Zoomout

Progress in the understanding and management of pulmonary arterial hypertension, Page 1 of 1

| /docserver/preview/fulltext/gcsp/2015/1/gcsp.2015.13-1.gif

Loading

Article metrics loading...

/content/journals/10.5339/gcsp.2015.13
2015-04-04
2020-11-24
Loading full text...

Full text loading...

/deliver/fulltext/gcsp/2015/1/gcsp.2015.13.html?itemId=/content/journals/10.5339/gcsp.2015.13&mimeType=html&fmt=ahah

References

  1. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT, Levy PS, Pietra GG, Reid LM, Reeves JT, Rich S, Vreim CE, Williams GW, Wu M. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Annals of Internal Medicine. 1991; 115:5:343349.
    [Google Scholar]
  2. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Koerner SK. Primary pulmonary hypertension. A national prospective study. Annals of Internal Medicine. 1987; 107:2:216223.
    [Google Scholar]
  3. McGoon MD, Benza RL, Escribano-Subias P, Jiang X, Miller DP, Peacock AJ, Pepke-Zaba J, Pulido T, Rich S, Rosenkranz S, Suissa S, Humbert M. Pulmonary arterial hypertension: epidemiology and registries. Journal of the American College of Cardiology. 2013; 62:25, Supplement:D51D59.
    [Google Scholar]
  4. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the reveal registry. Chest. 2012; 142:2:448456.
    [Google Scholar]
  5. Escribano-Subias P, Blanco I, López-Meseguer M, Lopez-Guarch CJ, Roman A, Morales P, Castillo-Palma MJ, Segovia J, Gómez-Sanchez MA, Barberà JA. Survival in pulmonary hypertension in Spain: insights from the Spanish registry. European Respiratory Journal. 2012; 40:3:596603.
    [Google Scholar]
  6. Humbert M, Sitbon O, Yaïci A, Montani D, O'Callaghan DS, Jaïs X, Parent F, Savale L, Natali D, Günther S, Chaouat A, Chabot F, Cordier J-F, Habib G, Gressin V, Jing ZC, Souza R, Simonneau G. French Pulmonary Arterial Hypertension Network. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. European Respiratory Journal. 2010; 36:3:549555.
    [Google Scholar]
  7. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaïci A, Weitzenblum E, Cordier J-F, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Cottin V, Degano B, Jaïs X, Montani D, Souza R. Survival in patients With idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010; 122:2:156163.
    [Google Scholar]
  8. Ling Y, Johnson MK, Kiely DG, Condliffe R, Elliot CA, Gibbs JSR, Howard LS, Pepke-Zaba J, Sheares KKK, Corris PA, Fisher AJ, Lordan JL, Gaine S, Coghlan JG, Wort SJ, Gatzoulis MA, Peacock AJ. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine. 2012; 186:8:790796.
    [Google Scholar]
  9. Zaiman A, Fijalkowska I, Hassoun PM, Tuder RM. One hundred years of research in the pathogenesis of pulmonary hypertension. American Journal of Respiratory Cell and Molecular Biology. 2005; 33:5:425431.
    [Google Scholar]
  10. ElMaghawry M, Zanatta A, Zampieri F. The discovery of pulmonary circulation: From Imhotep to William Harvey. Global Cardiology Science and Practice. 2014; 2014:2:31.
    [Google Scholar]
  11. West JB. Ibn al-Nafis, the pulmonary circulation, and the Islamic Golden Age. Journal of Applied Physiology. 2008; 105:6:18771880.
    [Google Scholar]
  12. Klob, Wien Wochenbl. 1865; 31::45.
    [Google Scholar]
  13. Van Wolferen SA, Grünberg K, Vonk Noordegraaf A. Diagnosis and management of pulmonary hypertension over the past 100 years. Respiratory Medicine. 2007; 101:3:389398.
    [Google Scholar]
  14. Von Romberg E. Uber sklerose der lungen arterie. Dtsch Arch Klin Med. 1891; 48::197206.
    [Google Scholar]
  15. Mazzei JA, Mazzei ME. A tribute: Abel Ayerza and pulmonary hypertension. European Respiratory Review. 2011; 20:122:220221.
    [Google Scholar]
  16. Arrillaga. Sclerose de l'artere pulmonaire secondaire à certeins ètats pulmonaire chronique (Cardiaques Noirs). Arch Mal Coeur. 1913; 6::518529.
    [Google Scholar]
  17. Brenner OO. Pathology of the vessels of the pulmonary circulation: Part I. Archives of Internal Medicine. 1935; 56:2:211237.
    [Google Scholar]
  18. Fishman AP. Primary pulmonary arterial hypertension: A look back. Journal of the American College of Cardiology. 2004; 43:12, Supplement:S2S4.
    [Google Scholar]
  19. Forssmann DW. Die Sondierung des Rechten Herzens. Klinische Wochenschrift. 1929; 8:45:20852087.
    [Google Scholar]
  20. Cournand A, Ranges HA. Catheterization of the right auricle in man. Experimental Biology and Medicine. 1941; 46:3:462466.
    [Google Scholar]
  21. Cournand A. Pulmonary circulation: Its control in man, with some remarks on methodology. Science. 1957; 125:3260:12311235.
    [Google Scholar]
  22. Cournand A, Riley RL, Breed ES, Baldwin ED, Richards DW, Lester MS, Jones M. Measurement of cardiac output in man using the technique of catherization of the right auricle of ventricle. Journal of Clinical Investigation. 1945; 24:1:106116.
    [Google Scholar]
  23. Richards DW. Right heart catheterization its contributions to physiology and medicine. Science. 1957; 125:3259:11811185.
    [Google Scholar]
  24. Dresdale DT, Schultz M, Michtom RJ. Primary pulmonary hypertension: I. Clinical and hemodynamic study. The American Journal of Medicine. 1951; 11:6:686705.
    [Google Scholar]
  25. Wood P. Pulmonary hypertension. British Medical Bulletin. 1952; 8:4:348353.
    [Google Scholar]
  26. Dresdale DT, Michtom RJ, Schultz M. Recent studies in primary pulmonary hypertension including pharmacodynamic observations on pulmonary vascular resistance. Bulletin of the New York Academy of Medicine. 1954; 30:3:195207.
    [Google Scholar]
  27. Harris P. Influence of acetylcholine on the pulmonary arterial pressure. British Heart Journal. 1957; 19:2:272278.
    [Google Scholar]
  28. Hatano S, Strasser T. Primary pulmonary hypertension: Report on a WHO meeting Geneva 15-17 October 1973. World Health Organisation 1975.
    [Google Scholar]
  29. Gurtner HP, Gertsch M, Salzmann C, Scherrer M, Stucki P, Wyss F. [Are the primary vascular forms of chronic pulmonary heart disease becoming more common?]. Schweizerische Medizinische Wochenschrift. 1968; 98:41:15791589.
    [Google Scholar]
  30. Gurtner HP. Aminorex and pulmonary hypertension. Cor Et Vasa. 1985; 27:2:160171.
    [Google Scholar]
  31. Reitz BA, Wallwork JL, Hunt SA, Pennock JL, Billingham ME, Oyer PE, Stinson EB, Shumway NE. Heart-lung transplantation: Successful therapy of patients with pulmonary vascular disease. New England Journal of Medicine. 1982; 306:10:557564.
    [Google Scholar]
  32. Rich S, Brundage BH. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: Evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation. 1987; 76:1:135141.
    [Google Scholar]
  33. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. New England Journal of Medicine. 1992; 327:2:7681.
    [Google Scholar]
  34. Frank H, Mlczoch J, Huber K, Schuster E, Gurtner HP, Kneussl M. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest. 1997; 112:3:714721.
    [Google Scholar]
  35. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: Natural history and the importance of thrombosis. Circulation. 1984; 70:4:580587.
    [Google Scholar]
  36. Olsson KM, Delcroix M, Ghofrani HA, Tiede H, Huscher D, Speich R, Grünig E, Staehler G, Rosenkranz S, Halank M, Held M, Lange TJ, Behr J, Klose H, Claussen M, Ewert R, Opitz CF, Vizza CD, Scelsi L, Vonk-Noordegraaf A, Kaemmerer H. Anticoagulation and survival in pulmonary arterial hypertension results from the comparative, prospective registry of newly initiated therapies for pulmonary hypertension (COMPERA). Circulation. 2014; 129:1:5765.
    [Google Scholar]
  37. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976; 263:5579:663665.
    [Google Scholar]
  38. Hyman AL, Chapnick BM, Kadowitz PJ, Lands WE, Crawford CG, Fried J, Barton J. Unusual pulmonary vasodilator activity of 13,14-dehydroprostacyclin methyl ester: comparison with endoperoxides and other prostanoids. Proceedings of the National Academy of Sciences of the United States of America. 1977; 74:12:57115715.
    [Google Scholar]
  39. Rubin LJ, Groves BM, Reeves JT, Frosolono M, Handel F, Cato AE. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation. 1982; 66:2:334338.
    [Google Scholar]
  40. Higenbottam T, Wheeldon D, Wells F, Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet. 1984; 1:8385:10461047.
    [Google Scholar]
  41. Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, Diehl JH, Crow J, Long W. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Annals of Internal Medicine. 1990; 112:7:485491.
    [Google Scholar]
  42. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Clayton LM, Jöbsis MM, Blackburn SD, Shortino D, Crow JW. Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. New England Journal of Medicine. 1996; 334:5:296301.
    [Google Scholar]
  43. Rich S. Executive Summary from the World Symposium on Primary Pulmonary Hypertension 1998. World Health Organisation 1998.
    [Google Scholar]
  44. Simonneau G, Barst R, Galiè N, Naeije R, Rich S, Bourge RC, Keogh AM, Oudiz RJ, Frost AE, Blackburn SD, Crow JW, Rubin LJ. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients withpulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine. 2002; 165:6:800804.
    [Google Scholar]
  45. Hoeper MM, Schwarze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetter E, Niedermeyer J, Hamm M, Fabel H. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. New England Journal of Medicine. 2000; 342:25:18661870.
    [Google Scholar]
  46. Olschewski H, Simonneau G, Galiè N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M. Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. New England Journal of Medicine. 2002; 347:5:322329.
    [Google Scholar]
  47. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, Rubin LJ. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study. The Lancet. 2001; 358:9288:11191123.
    [Google Scholar]
  48. Chester AH, Yacoub MH. The role of endothelin-1 in pulmonary arterial hypertension. Global Cardiology Science and Practice. 2014; 2014:2:29.
    [Google Scholar]
  49. Rubin LJ, Badesch DB, Barst RJ, Galiè N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G. Bosentan therapy for pulmonary arterial hypertension. New England Journal of Medicine. 2002; 346:12:896903.
    [Google Scholar]
  50. Atz AM, Wessel DL. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology. 1999; 91:1:307310.
    [Google Scholar]
  51. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension comparison with inhaled nitric oxide. Circulation. 2002; 105:20:23982403.
    [Google Scholar]
  52. Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension. New England Journal of Medicine. 2000; 343:18:13421342.
    [Google Scholar]
  53. Sastry BKS, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo-controlled, double-blind, crossover study. Journal of the American College of Cardiology. 2004; 43:7:11491153.
    [Google Scholar]
  54. Simonneau G, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A. Clinical classification of pulmonary hypertension. Journal of the American College of Cardiology. 2004; 43:12, Supplement:S5S12.
    [Google Scholar]
  55. Galiè N, Seeger W, Naeije R, Simonneau G, Rubin LJ. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. Journal of the American College of Cardiology. 2004; 43:12, Supplement:S81S88.
    [Google Scholar]
  56. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G. Sildenafil citrate therapy for pulmonary arterial hypertension. New England Journal of Medicine. 2005; 353:20:21482157.
    [Google Scholar]
  57. Humbert M, McLaughlin VV. The 4th world symposium on pulmonary hypertension. Journal of the American College of Cardiology. 2009; 54:1, Supplement:S1S2.
    [Google Scholar]
  58. Barst RJ, Gibbs JSR, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, Sitbon O, Tapson VF, Galiè N. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. Journal of the American College of Cardiology. 2009; 54:1, Supplement:S78S84.
    [Google Scholar]
  59. McLaughlin VV, Badesch DB, Delcroix M, Fleming TR, Gaine SP, Galiè N, Gibbs JSR, Kim NH, Oudiz RJ, Peacock A, Provencher S, Sitbon O, Tapson VF, Seeger W. End points and clinical trial design in pulmonary arterial hypertension. Journal of the American College of Cardiology. 2009; 54:1, Supplement:S97S107.
    [Google Scholar]
  60. Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani H-A, Jansa P, Jing Z-C, Le Brun F-O, Mehta S, Mittelholzer CM, Perchenet L, Sastry BKS, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G, SERAPHIN Investigators . SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension. New England Journal of Medicine. 2013; 369:9:809818.
    [Google Scholar]
  61. Ghofrani H-A, Galiè N, Grimminger F, Grünig E, Humbert M, Jing Z-C, Keogh AM, Langleben D, Kilama MO, Fritsch A, Neuser D, Rubin LJ. Riociguat for the treatment of pulmonary arterial hypertension. New England Journal of Medicine. 2013; 369:4:330340.
    [Google Scholar]
  62. Ghofrani H-A, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, Mayer E, Simonneau G, Wilkins MR, Fritsch A, Neuser D, Weimann G, Wang C. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. New England Journal of Medicine. 2013; 369:4:319329.
    [Google Scholar]
  63. Galiè N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, Klepetko W, McGoon MD, McLaughlin VV, Preston IR, Rubin LJ, Sandoval J, Seeger W, Keogh A. Updated treatment algorithm of pulmonary arterial hypertension. Journal of the American College of Cardiology. 2013; 62:25, Supplement:D60D72.
    [Google Scholar]
  64. Tuder RM, Archer SL, Dorfmüller P, Erzurum SC, Guignabert C, Michelakis E, Rabinovitch M, Schermuly R, Stenmark KR, Morrell NW. Relevant issues in the pathology and pathobiology of pulmonary hypertension. Journal of the American College of Cardiology. 2013; 62:25, Supplement:D4D12.
    [Google Scholar]
  65. GlaxoSmithKline. A study of first-line ambrisentan and tadalafil combination therapy in subjects with pulmonary arterial hypertension (PAH) (AMBITION). 2014;. http://clinicaltrials.gov/show/NCT01178073.
    [Google Scholar]
  66. Simonneau G, Torbicki A, Hoeper MM, Delcroix M, Karlócai K, Galiè N, Degano B, Bonderman D, Kurzyna M, Efficace M, Giorgino R, Lang IM. Selexipag: An oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. The European Respiratory Journal. 2012; 40:4:874880.
    [Google Scholar]
  67. Actelion. Selexipag (ACT-293987) in pulmonary arterial hypertension, GRIPHON Trial. 2014;, http://clinicaltrials.gov/ct2/show/NCT01106014.
    [Google Scholar]
  68. Wilkins MR, Ali O, Bradlow W, Wharton J, Taegtmeyer A, Rhodes CJ, Ghofrani HA, Howard L, Nihoyannopoulos P, Mohiaddin RH, Gibbs JSR. Simvastatin Pulmonary Hypertension Trial (SiPHT) Study Group. Simvastatin as a treatment for pulmonary hypertension trial. American Journal of Respiratory and Critical Care Medicine. 2010; 181:10:11061113.
    [Google Scholar]
  69. Fukumoto Y, Matoba T, Ito A, Tanaka H, Kishi T, Hayashidani S, Abe K, Takeshita A, Shimokawa H. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart. 2005; 91:3:391392.
    [Google Scholar]
  70. Fukumoto Y, Yamada N, Matsubara H, Mizoguchi M, Uchino K, Yao A, Kihara Y, Kawano M, Watanabe H, Takeda Y, Adachi T, Osanai S, Tanabe N, Inoue T, Kubo A, Ota Y, Fukuda K, Nakano T, Shimokawa H. Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension. Circulation Journal: Official Journal of the Japanese Circulation Society. 2013; 77:10:26192625.
    [Google Scholar]
  71. Loyd JE, Primm RK, Newman JH. Familial primary pulmonary hypertension: Clinical patterns. The American Review of Respiratory Disease. 1984; 129:1:194197.
    [Google Scholar]
  72. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, Kalachikov S, Cayanis E, Fischer SG, Barst RJ, Hodge SE, Knowles JA. Familial primary pulmonary hypertension (Gene PPH1) is caused by mutations in the bone morphogenetic protein receptor–II gene. The American Journal of Human Genetics. 2000; 67:3:737744.
    [Google Scholar]
  73. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA, Loyd JE, Nichols WC, Trembath RC. Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension. Nature Genetics. 2000; 26:1:8184.
    [Google Scholar]
  74. Soubrier F, Chung WK, Machado R, Grünig E, Aldred M, Geraci M, Loyd JE, Elliott CG, Trembath RC, Newman JH, Humbert M. Genetics and genomics of pulmonary arterial hypertension. Journal of the American College of Cardiology. 2013; 62:25, Supplement:D13D21.
    [Google Scholar]
  75. Upton PD, Morrell NW. The transforming growth factor-β–bone morphogenetic protein type signalling pathway in pulmonary vascular homeostasis and disease. Experimental Physiology. 2013; 98:8:12621266.
    [Google Scholar]
  76. Machado RD, Eickelberg O, Elliott CG, Geraci MW, Hanaoka M, Loyd JE, Newman JH, Phillips SoubrierF III JA, Trembath RC, Chung WK. Genetics and genomics of pulmonary arterial hypertension. Journal of the American College of Cardiology. 2009; 54:1, Supplement:S32S42.
    [Google Scholar]
  77. Rabinovitch M, Guignabert C, Humbert M, Nicolls MR. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circulation Research. 2014; 115:1:165175.
    [Google Scholar]
  78. Saco TV, Parthasarathy PT, Cho Y, Lockey RF, Kolliputi N. Role of epigenetics in pulmonary hypertension. American Journal of Physiology - Cell Physiology. 2014; 306:12:C1101C1105.
    [Google Scholar]
  79. Paulin R, Michelakis ED. The metabolic theory of pulmonary arterial hypertension. Circulation Research. 2014; 115:1:148164.
    [Google Scholar]
  80. Hoeper MM, Barst RJ, Bourge RC, Feldman J, Frost AE, Galié N, Gómez-Sánchez MA, Grimminger F, Grünig E, Hassoun PM, Morrell NW, Peacock AJ, Satoh T, Simonneau G, Tapson VF, Torres F, Lawrence D, Quinn DA, Ghofrani HA. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: Results of the randomized IMPRES study. Circulation. 2013; 127:10:11281138.
    [Google Scholar]
  81. Godinas L, Guignabert C, Seferian A, Perros F, Bergot E, Sibille Y, Humbert M, Montani D. Tyrosine kinase inhibitors in pulmonary arterial hypertension: A double-edge sword? Seminars in Respiratory and Critical Care Medicine. 2013; 34:5:714724.
    [Google Scholar]
  82. Novartis. Efficacy, safety, tolerability and pharmacokinetics (PK) of nilotinib (AMN107) in pulmonary arterial hypertension (PAH). 2014;. http://clinicaltrials.gov/ct2/show/results/NCT01179737.
    [Google Scholar]
  83. Spiekerkoetter E. FK506 (tacrolimus) in pulmonary arterial hypertension (TransformPAH). 2012;. http://clinicaltrials.gov/show/NCT01647945.
    [Google Scholar]
  84. Michelakis E, Wilkins MR. Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension. 2014;. http://clinicaltrials.gov/show/NCT01083524.
    [Google Scholar]
  85. Taniguchi K, Shimazaki C, Fujimoto Y, Shimura K, Uchiyama H, Matsumoto Y, Kuroda J, Horiike S, Taniwaki M. Tocilizumab is effective for pulmonary hypertension associated with multicentric Castleman's disease. International Journal of Hematology. 2009; 90:1:99102.
    [Google Scholar]
  86. Furuya Y, Satoh T, Kuwana M. Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension. International Journal of Rheumatology. 2010; 2010::720305.
    [Google Scholar]
  87. Kadavath S, Zapantis E, Zolty R, Efthimiou P. A novel therapeutic approach in pulmonary arterial hypertension as a complication of adult-onset Still's disease: Targeting IL-6. International Journal of Rheumatic Diseases. 2014; 17:3:336340.
    [Google Scholar]
  88. Ohira H, Beanlands RS, Davies RA, Mielniczuk L. The role of nuclear imaging in pulmonary hypertension. Journal of Nuclear Cardiology. 2014;117.
    [Google Scholar]
  89. Reynolds AM, Holmes MD, Danilov SM, Reynolds PN. Targeted gene delivery of BMPR2 attenuates pulmonary hypertension. European Respiratory Journal. 2012; 39:2:329343.
    [Google Scholar]
  90. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordoñez C, Elborn JS. VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine. 2011; 365:18:16631672.
    [Google Scholar]
  91. Montani D, Chaumais M-C, Guignabert C, Günther S, Girerd B, Jaïs X, Algalarrondo V, Price LC, Savale L, Sitbon O, Simonneau G, Humbert M. Targeted therapies in pulmonary arterial hypertension. Pharmacology & Therapeutics. 2014; 141:2:172191.
    [Google Scholar]
  92. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, Olschewski H, Robbins IM, Souza R. Updated Clinical Classification of Pulmonary Hypertension. Journal of the American College of Cardiology. 2013; 62:25_S.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/gcsp.2015.13
Loading
/content/journals/10.5339/gcsp.2015.13
Loading

Data & Media loading...

  • Article Type: Research Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error